Psoriatic Arthritis: Guselkumab for Enthesitis

We are studying whether Guselkumab can help reduce inflammation in patients with psoriatic arthritis who have not received prior treatments. This trial focuses on those with ultrasound-confirmed enthesitis.

1-2 years 6-10 visits Monitoring phase (IV)No Placebo Standard Medicines InjectionInfectious DiseasesRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Tremfya

Tremfya is a medicine used to treat moderate to severe plaque psoriasis and to help relieve symptoms of psoriatic arthritis.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Guselkumab

Guselkumab is a lab-made antibody that blocks an immune signal to reduce inflammation in people with moderate-to-severe plaque psoriasis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Charite Universitaetsmedizin Berlin KöR

Department of Rheumatology and Clinical Immunology

Berlin, Germany

Krankenhaus Porz Am Rhein gGmbH

Department of Rheumatology

Eil, Germany

Universitaetsklinikum Erlangen AöR

Department of Medicine 3 - Rheumatology and Immunology

Erlangen, Germany

Sponsor: Universitaetsklinikum Erlangen AöR

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.